Trial Profile
A Placebo-Controlled, Double-Blind, Parallel, Randomized, Two-Part, Clinical Dose-Confirming Study Of Pulsed, Inhaled Nitric Oxide (iNO) In Subjects With World Health Organization (WHO) Group 3 Pulmonary Hypertension (PH) Associated With Chronic Obstructive Pulmonary Disease (COPD) On Long Term Oxygen Therapy (LTOT) INHALE 1
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Mar 2023
Price :
$35
*
At a glance
- Drugs Nitric oxide (Primary)
- Indications Pulmonary hypertension
- Focus Therapeutic Use
- Acronyms INHALE 1
- Sponsors Bellerophon Therapeutics
- 25 Jan 2012 New trial record